LOS ANGELES, Aug. 30, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against TransDigm Group Incorporated (“TransDigm” or the “Company”) (NYSE:TDG) for possible violations of federal securities laws between May 10, 2016 and January 19, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired TransDigm shares during the Class Period should contact the firm prior to the October 10, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, TransDigm made false and/or misleading statements and/or failed to disclose: that the Company’s growth and profitability were artificially inflated because of its illicit business practices; that TransDigm used exclusive distributors to make noncompetitive government bids seems competitive; that the Company’s subsidiaries failed to list TransDigm as a parent entity when submitting government bids; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this information was released, shares of TransDigm decreased in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 



